Diabeloop and EOFlow team up to develop an automated insulin device
pharmafile | January 13, 2023 | News story | Medical Communications |
Diabeloop, a medical device company focused on automated diabetes treatment solutions, and South Korea-based EOFlow have joined forces to offer patients access to EOFlow’s EOPatch system, which will be powered by Diabeloop’s automated insulin delivery (AID) algorithm.
EOPatch is a wearable insulin pump which is disposable and tubeless. Under the deal, EOPatch will be combined with Diabeloop’s DBLG1 System, a smartphone app-based, integrated AID algorithm, and a third-party continuous glucose monitoring (CGM) device.
Diabeloop co-founder and CEO Erik Huneker stated, “It is an honour to partner with EOFlow and combine our state-of-the-art automated insulin delivery algorithm with their innovative wearable insulin pump solution. Diabeloop and EOFlow share the same goal to offer choices to people living with diabetes by providing advanced and user-friendly solutions. We confirmed the technical feasibility of our integration through a Hackathon last summer, and we are expanding this as an official development agreement to commercialise a combined solution.”
“In the field of automated insulin delivery, the adaptability and scalability of our wearable insulin pump is limitless, and we are working toward placing ourselves in a leadership position. While we continue to commercialise EOPatch X, our artificial pancreas solution, we’re excited to kick off this partnership with Diabeloop and bring a wearable AID option to users sooner. We are also eager to make the smartphone app available in the European market,” followed OFlow founder and CEO Jesse J Kim.